CSL Behring (GREAT) Hereditary Angioedema (HAE) Study

If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.

CSL BEHRING (GREAT) AGE 12 YEARS AND OLDER (HAE STUDY)

  • This is a multinational, multicenter, prospective observational cohort study of patients with HAE in the real-world setting.
  • The study will include patients newly initiating garadacimab in routine clinical practice in accordance with the indication.
  • Patients will be enrolled at the time of prescription of garadacimab per routine clinical practice, and the index date will be defined as the date of initiation of garadacimab (i.e., first administration).
  • Each patient will be followed up to 48 months after index date (date of first administration of garadacimab). No research site visits are required.
  • Patient data will be collected from the HAE diary, patient medical records and/or during a routine clinical visit.

Key Inclusion Criteria:

  • Patients aged ≥ 12 years at enrollment.
  • Patients with clinical and/or laboratory confirmed diagnosis of HAE.
  • Patients newly initiating garadacimab.

Key Exclusion Criteria:

  • Patients with a concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticaria.
Learn More About Our Current Studies

Interested in This Research Study?

If you’d like to learn more or see whether you may be eligible to participate, please complete the brief interest form below. A member of our research team will follow up with next steps.

Apply Below

Research Study Interest Form

To learn more or express interest in this study, please complete the form below or contact our research team at 502-368-0732.

  • This field is for validation purposes and should be left unchanged.

SCHEDULE APPOINTMENT: CALL 800.999.1249 OR SCHEDULE ONLINE